Skip to content
Back to BBTX

Bambusa Therapeutics, Inc.

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 16, 2025
Transactions
6
Purchases
6
Sales
0
Purchase value
$52.64M
Sale value
$0.00

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

Peter KolchinskyDirector · 10% owner
Capital Healthcare Fund LP RADirector · 10% owner
L.P. RA Capital ManagementDirector · 10% owner
L.P. RA Capital Nexus Fund IIIDirector
Rajeev M. ShahDirector · 10% owner
4
Filed Nov 3, 2026Period of report Oct 30, 20260001231919-26-001533
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseNov 2, 2026
Common StockF2F32,335,109$16.00$37.36M5,933,787IndirectSee footnotes
PurchaseNov 2, 2026
Common StockF2F6164,891$16.00$2.64M1,495,971IndirectSee footnotes
PurchaseOct 30, 2026
Common StockF1F2F3189,909$14.23$2.70M189,909IndirectSee footnotes
PurchaseOct 30, 2026
Common StockF4F2F3263,911$14.92$3.94M453,820IndirectSee footnotes
Filing footnotes · 6
  1. F1The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.61 to $14.58 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  2. F2RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
  3. F3Held directly by the Fund.
  4. F4The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.65 to $15.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  5. F5All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock.
  6. F6Held directly by the Nexus Fund III.
Open on SEC EDGAR
Salvia Investment GmbH10% owner
4
Filed Nov 2, 2026Period of report Nov 2, 20260002162499-26-000004
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseNov 2, 2026
Common Stock375,000$16.00$6.00M9,264,301Direct
Filing footnotes · 1
  1. F1All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock.
Open on SEC EDGAR
Helmut Wolfgang JeggleDirector · 10% owner
4
Filed Nov 2, 2026Period of report Nov 2, 20260001982614-26-000004
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseNov 2, 2026
Common StockF2375,000$16.00$6.00M9,264,301IndirectSee footnote
Filing footnotes · 2
  1. F1All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock.
  2. F2Shares held by Salvia Investment GmbH ("Salvia"). The Reporting Person is the Managing Director of Salvia GmbH and has sole voting and dispositive power with respect to the shares held by Salvia. The Reporting Person disclaims beneficial ownership of such holdings, except to the extent of his pecuniary interest in the shares.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.